Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
3(60.0%)
N/A
2(40.0%)
5Total
Phase 1(3)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07556120Phase 1Not Yet Recruiting

Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)

Role: lead

NCT06801119Phase 1Recruiting

Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）

Role: lead

NCT07523282Phase 1Not Yet Recruiting

Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases

Role: lead

NCT07413835Not ApplicableRecruiting

Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)

Role: collaborator

NCT06965309Not ApplicableTerminated

Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)

Role: lead

All 5 trials loaded